Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy | Zendy

Chui Ming Gemmy Cheung | Zendy; Timothy Y. Y. Lai | Zendy; Fumi Gomi | Zendy; Paisan Ruamviboonsuk | Zendy; Adrian Koh | Zendy; Won Ki Lee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy

Author(s) -

Chui Ming Gemmy Cheung,

Timothy Y. Y. Lai,

Fumi Gomi,

Paisan Ruamviboonsuk,

Adrian Koh,

Won Ki Lee

Publication year - 2017

Publication title -

asia-pacific journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.163

H-Index - 20

ISSN - 2162-0989

DOI - 10.22608/apo.2017260

Subject(s) - macular degeneration , medicine , photodynamic therapy , bevacizumab , combination therapy , oncology , clinical trial , vegf receptors , vascular endothelial growth factor , ophthalmology , randomized controlled trial , chemotherapy , chemistry , organic chemistry

Anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of neovascular age-related macular degeneration (AMD). This review will summarize the current evidence of anti-VEGF therapy in neovascular AMD, including subtypes of retinal angiomatous proliferation and polypoidal choroidal vasculopathy (PCV). Importantly, 2 large multicenter randomized clinical trials evaluating the safety and efficacy of anti-VEGF monotherapy and combination with photodynamic therapy (PDT) have recently reported initial first-year outcomes. In this review, we summarize the latest updates in the efficacy and safety of anti-VEGF monotherapy and combination with PDT in common lesion subtypes. Remaining gaps in current understanding are highlighted where further research is needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research